Annual EBITDA
-$77.23 M
+$10.07 M+11.53%
December 31, 2023
Summary
- As of February 8, 2025, XLO annual EBITDA is -$77.23 million, with the most recent change of +$10.07 million (+11.53%) on December 31, 2023.
- During the last 3 years, XLO annual EBITDA has fallen by -$23.73 million (-44.37%).
- XLO annual EBITDA is now -311.10% below its all-time high of -$18.79 million, reached on December 31, 2019.
Performance
XLO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$14.42 M
-$193.00 K-1.36%
September 30, 2024
Summary
- As of February 8, 2025, XLO quarterly EBITDA is -$14.42 million, with the most recent change of -$193.00 thousand (-1.36%) on September 30, 2024.
- Over the past year, XLO quarterly EBITDA has increased by +$3.26 million (+18.43%).
- XLO quarterly EBITDA is now -1.36% below its all-time high of -$14.23 million, reached on June 30, 2024.
Performance
XLO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$62.43 M
+$2.48 M+3.82%
September 30, 2024
Summary
- As of February 8, 2025, XLO TTM EBITDA is -$62.43 million, with the most recent change of +$2.48 million (+3.82%) on September 30, 2024.
- Over the past year, XLO TTM EBITDA has increased by +$14.80 million (+19.17%).
- XLO TTM EBITDA is now -336.35% below its all-time high of -$14.31 million, reached on September 30, 2020.
Performance
XLO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
XLO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +11.5% | +18.4% | +19.2% |
| 3 y3 years | -44.4% | +18.4% | +19.2% |
| 5 y5 years | - | +18.4% | +19.2% |
XLO EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -5.0% | +11.5% | -1.4% | +40.2% | at high | +30.3% |
| 5 y | 5-year | -311.1% | +11.5% | -1.4% | +40.2% | -336.4% | +30.3% |
| alltime | all time | -311.1% | +11.5% | -1.4% | +40.2% | -336.4% | +30.3% |
Xilio Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$14.42 M(+1.4%) | -$62.43 M(-3.8%) |
| Jun 2024 | - | -$14.23 M(-11.6%) | -$64.91 M(-7.7%) |
| Mar 2024 | - | -$16.10 M(-9.0%) | -$70.30 M(-9.0%) |
| Dec 2023 | -$77.23 M(-11.5%) | -$17.68 M(+4.6%) | -$77.23 M(-6.1%) |
| Sep 2023 | - | -$16.90 M(-13.9%) | -$82.23 M(-3.3%) |
| Jun 2023 | - | -$19.62 M(-14.8%) | -$85.06 M(-5.0%) |
| Mar 2023 | - | -$23.03 M(+1.5%) | -$89.55 M(+2.6%) |
| Dec 2022 | -$87.30 M | -$22.68 M(+14.9%) | -$87.30 M(+4.2%) |
| Sep 2022 | - | -$19.73 M(-18.1%) | -$83.79 M(+5.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$24.11 M(+16.0%) | -$79.63 M(+1.9%) |
| Mar 2022 | - | -$20.78 M(+8.5%) | -$78.16 M(+6.3%) |
| Dec 2021 | -$73.55 M(+37.5%) | -$19.16 M(+23.0%) | -$73.55 M(-1.5%) |
| Sep 2021 | - | -$15.58 M(-31.2%) | -$74.64 M(+1.7%) |
| Jun 2021 | - | -$22.63 M(+40.0%) | -$73.36 M(+44.6%) |
| Mar 2021 | - | -$16.17 M(-20.2%) | -$50.73 M(+46.8%) |
| Dec 2020 | -$53.50 M(+184.8%) | -$20.25 M(+41.6%) | -$34.56 M(+141.6%) |
| Sep 2020 | - | -$14.31 M | -$14.31 M |
| Dec 2019 | -$18.79 M | - | - |
FAQ
- What is Xilio Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Xilio Therapeutics?
- What is Xilio Therapeutics annual EBITDA year-on-year change?
- What is Xilio Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Xilio Therapeutics?
- What is Xilio Therapeutics quarterly EBITDA year-on-year change?
- What is Xilio Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Xilio Therapeutics?
- What is Xilio Therapeutics TTM EBITDA year-on-year change?
What is Xilio Therapeutics annual EBITDA?
The current annual EBITDA of XLO is -$77.23 M
What is the all time high annual EBITDA for Xilio Therapeutics?
Xilio Therapeutics all-time high annual EBITDA is -$18.79 M
What is Xilio Therapeutics annual EBITDA year-on-year change?
Over the past year, XLO annual EBITDA has changed by +$10.07 M (+11.53%)
What is Xilio Therapeutics quarterly EBITDA?
The current quarterly EBITDA of XLO is -$14.42 M
What is the all time high quarterly EBITDA for Xilio Therapeutics?
Xilio Therapeutics all-time high quarterly EBITDA is -$14.23 M
What is Xilio Therapeutics quarterly EBITDA year-on-year change?
Over the past year, XLO quarterly EBITDA has changed by +$3.26 M (+18.43%)
What is Xilio Therapeutics TTM EBITDA?
The current TTM EBITDA of XLO is -$62.43 M
What is the all time high TTM EBITDA for Xilio Therapeutics?
Xilio Therapeutics all-time high TTM EBITDA is -$14.31 M
What is Xilio Therapeutics TTM EBITDA year-on-year change?
Over the past year, XLO TTM EBITDA has changed by +$14.80 M (+19.17%)